Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ASMB
stocks logo

ASMB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.60M
+44.02%
-0.535
-65.92%
9.03M
-4.09%
-0.847
-27.64%
7.80M
-18.97%
-0.967
-27.32%
Estimates Revision
The market is revising Downward the revenue expectations for Assembly Biosciences, Inc. (ASMB) for FY2025, with the revenue forecasts being adjusted by -4.55% over the past three months. During the same period, the stock price has changed by 48.10%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.23%
In Past 3 Month
Stock Price
Go Up
up Image
+48.10%
In Past 3 Month
Wall Street analysts forecast ASMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASMB is 41.75 USD with a low forecast of 38.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ASMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASMB is 41.75 USD with a low forecast of 38.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.270
sliders
Low
38.00
Averages
41.75
High
50.00
Current: 35.270
sliders
Low
38.00
Averages
41.75
High
50.00
Mizuho
Salim Syed
maintain
$29 -> $40
2025-11-20
Reason
Mizuho
Salim Syed
Price Target
$29 -> $40
2025-11-20
maintain
Reason
Mizuho analyst Salim Syed raised the firm's price target on Assembly Biosciences to $40 from $29 and keeps an Outperform rating on the shares. The firm updated the company's model to reflect the recent positive ABI-5366 data.
Citizens JMP
Roy Buchanan
Outperform
initiated
$38
2025-09-24
Reason
Citizens JMP
Roy Buchanan
Price Target
$38
2025-09-24
initiated
Outperform
Reason
Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences with an Outperform rating and $38 price target. The firm believes the company's "strong early data point to likely best-in-class profiles" for both its oral candidates for treating herpes simplex virus is underappreciated at current share levels. Assembly's lead opportunity in treating recurrent genital herpes has blockbuster potential, the analyst tells investors in a research note.
Guggenheim
Buy
upgrade
$31 -> $39
2025-09-08
Reason
Guggenheim
Price Target
$31 -> $39
2025-09-08
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Assembly Biosciences to $39 from $31 and keeps a Buy rating on the shares. Following interim data from Assembly's Phase 1b study released last month that demonstrated "striking efficacy and a clean safety profile" for ABI-5366, the firm is increasing its view of the odds of success to 75% from 65% and increasing its assumed monthly price to $500 from $300 for what it calls "a potential blockbuster novel weekly or monthly treatment" for recurrent genital herpes.
H.C. Wainwright
Patrick Trucchio
initiated
$50
2025-08-18
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$50
2025-08-18
initiated
Reason
H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences with a Buy rating and $50 price target. The firm sees potential for the company's clinical-stage antiviral pipeline to deliver "significant value" in collaboration with Gilead Sciences (GILD).
Guggenheim
Vamil Divan
Strong Buy
Initiates
$31
2025-03-25
Reason
Guggenheim
Vamil Divan
Price Target
$31
2025-03-25
Initiates
Strong Buy
Reason
Guggenheim initiated coverage of Assembly Biosciences with a Buy rating and $31 price target.
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2025-03-24
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2025-03-24
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Assembly Biosciences Inc (ASMB.O) is -10.14, compared to its 5-year average forward P/E of -2.04. For a more detailed relative valuation and DCF analysis to assess Assembly Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.04
Current PE
-10.14
Overvalued PE
-0.10
Undervalued PE
-3.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.26
Undervalued EV/EBITDA
-2.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.12
Current PS
0.00
Overvalued PS
35.63
Undervalued PS
-13.38
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 161.98% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ASMB News & Events

Events Timeline

(ET)
2025-11-10
16:31:29
Assembly Biosciences announces Q3 earnings per share of 72 cents, surpassing consensus estimate of 65 cents.
select
2025-11-07 (ET)
2025-11-07
08:05:48
Assembly Biosciences Reveals Phase 1b Results for ABI-4334
select
2025-10-10 (ET)
2025-10-10
08:08:54
Assembly Biosciences unveils preliminary Phase 1b results for ABI-5366
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-21Benzinga
Mizuho Keeps Outperform Rating for Assembly Biosciences and Increases Price Target to $40

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.0
10-19NASDAQ.COM
IRON Strengthens, MNMD Offers Reassurance to Investors, Could NKTR Experience an Early Christmas?

  • Fidelity Investments Insight: Abigail Johnson emphasizes the importance of understanding investments, highlighting that successful investing is about knowing what you own and why.

  • Disc Medicine Inc. Update: The company submitted a New Drug Application for its drug Bitopertin to treat erythropoietic protoporphyria, receiving a priority voucher for expedited review, with stock reaching a 52-week high of $95.95.

  • Mind Medicine Inc. Developments: The company is preparing for pivotal data readouts in 2026 for its lead drug candidate, MM120, with stock hitting a 52-week high of $13.86.

  • Nektar Therapeutics Progress: The company reported significant results from its phase 2b trial for atopic dermatitis, with stock reaching a 52-week high of $63.92, and anticipates further data in early 2026.

[object Object]
Preview
9.0
10-10Newsfilter
Assembly Biosciences Unveils Interim Phase 1b Results for HSV Helicase-Primase Inhibitor ABI-5366 at the 38th IUSTI Europe Congress on Sexually Transmitted Infections

  • Interim Phase 1b Data Presentation: Assembly Biosciences presented interim Phase 1b data for its HSV helicase-primase inhibitor ABI-5366, showing significant reductions in HSV-2 shedding and genital lesions in participants receiving a 350 mg weekly dose compared to placebo.

  • Future Studies and Collaborations: The company plans to share additional data on ABI-5366 and another candidate, ABI-1179, later this fall, with Phase 2 studies for ABI-5366 expected to begin in mid-2026, under a collaboration agreement with Gilead Sciences.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Assembly Biosciences Inc (ASMB) stock price today?

The current price of ASMB is 35.27 USD — it has increased 0.77 % in the last trading day.

arrow icon

What is Assembly Biosciences Inc (ASMB)'s business?

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

arrow icon

What is the price predicton of ASMB Stock?

Wall Street analysts forecast ASMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASMB is 41.75 USD with a low forecast of 38.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Assembly Biosciences Inc (ASMB)'s revenue for the last quarter?

Assembly Biosciences Inc revenue for the last quarter amounts to 10.79M USD, increased 57.62 % YoY.

arrow icon

What is Assembly Biosciences Inc (ASMB)'s earnings per share (EPS) for the last quarter?

Assembly Biosciences Inc. EPS for the last quarter amounts to -0.72 USD, decreased -52.32 % YoY.

arrow icon

What changes have occurred in the market's expectations for Assembly Biosciences Inc (ASMB)'s fundamentals?

The market is revising Downward the revenue expectations for Assembly Biosciences, Inc. (ASMB) for FY2025, with the revenue forecasts being adjusted by -4.55% over the past three months. During the same period, the stock price has changed by 48.10%.
arrow icon

How many employees does Assembly Biosciences Inc (ASMB). have?

Assembly Biosciences Inc (ASMB) has 73 emplpoyees as of December 05 2025.

arrow icon

What is Assembly Biosciences Inc (ASMB) market cap?

Today ASMB has the market capitalization of 559.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free